DOCSLIB.ORG

WHO Systematic Review- Strategies for Addressing Vaccine Hesitancy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WHO Systematic Review- Strategies for Addressing Vaccine Hesitancy STRATEGIES FOR ADDRESSING VACCINE HESITANCY – A SYSTEMATIC REVIEW WHO SAGE working group dealing with vaccine hesitancy October 2014 TABLE OF CONTENTS Table of figures ............................................................................................................................................... 1 Table of tables ................................................................................................................................................ 3 Abbreviations .................................................................................................................................................. 4 Definitions………………………………………………………………………………………………………………………………………………….6 Acknowledgements ........................................................................................................................................ 7 Executive Summary…………………………………………………………………………………………………………………………………….8 SECTION 1 SYSTEMATIC LITERATURE REVIEW - STRATEGIES FOR ADDRESSING VACCINE HESITANCY ..................... 22 1.1 INTRODUCTION .................................................................................................................................... 22 1.1.a Objectives .................................................................................................................................................... 22 1.2 METHODS ............................................................................................................................................................ 23 1.2.a. Search methods .......................................................................................................................................... 23 1.2.b. Selection criteria ......................................................................................................................................... 25 1.2.c. Data extraction ........................................................................................................................................... 26 1.3 RESULTS .............................................................................................................................................................. 26 1.3.a. Literature identified .................................................................................................................................... 26 1.3.b. Scope of the literature and descriptive analyses ........................................................................................ 30 1.3.c. Summary of effects ......................................................................................................................... 43 1.4 SECTION SUMMARY .............................................................................................................................. 56 SECTION 2 EVALUATION OF THE VACCINE HESITANCY RESEARCH (PICO & GRADE) ................................................. 60 2.1 OBJECTIVES ......................................................................................................................................... 73 2.2 METHODS ........................................................................................................................................... 73 2.2.a Criteria for considering studies for this review ............................................................................................. 73 2.2.b Types of studies ............................................................................................................................................ 73 2.2.c Types of participants .................................................................................................................................... 73 2.2.d Types of interventions .................................................................................................................................. 73 2.2.e Types of outcome measures ......................................................................................................................... 74 2.2.f Search methods for identification of studies ................................................................................................. 74 2.2.g Data collection and analysis ............................................................................................................. 74 2.3 ASSESSMENT OF DATA QUALITY ............................................................................................................ 76 2.4 RESULTS .............................................................................................................................................. 77 2.4.a Description of studies ................................................................................................................................... 77 2.4.b Results of the search .................................................................................................................................... 77 2.4.c Included studies ............................................................................................................................................ 77 2.4.d Data analysis .................................................................................................................................. 82 2.5 SECTION SUMMARY ............................................................................................................................. 92 SECTION 3 SYNTHESIS OF FINDINGS, CONCLUSIONS AND IMPLICATIONS FOR RESEARCH & PRACTICE .............. ….132 3.1 SYNTHESIS OF FINDINGS ………………………………………………………………….......................................................... …….….132 3.2 CONCLUSIONS AND IMPLICATIONS …………………………………………………………………....................................................133 3.3 OPPORTUNITIES …………………………………………………………………..................................................................................134 3.4 LIMITATIONS ………………………………………………………………….......................................................................................134 3.5 IMPLICATIONS FOR RESEARCH AND PRACTICE…………………………………………………………………....................................135 4.1 REFERENCES………………………………………………………………….......................................................................136 5.1 APPENDICES ………………………………………………………………….......................................................................149 i 1 Table of figures Figure 1 Search process flow chart (peer reviewed literature) -vaccine hesitancy Figure 2 Search process flow chart (grey literature) -vaccine hesitancy Figure 3 Search process flow chart (grey literature) – reproductive health Figure 4 Evaluated and suggested peer reviewed and grey literature articles on vaccine hesitancy Figure 5 Evaluated peer reviewed strategies by publication year (2007-2013) and WHO region Figure 6 Evaluated grey literature articles by publication year (1996-2013) and WHO region Figure 7 Evaluated peer reviewed strategies by vaccine and WHO region (2007-2013) Figure 8 Evaluated grey literature strategies by vaccine and WHO region (1996-2013) Figure 9 Evaluated peer reviewed strategies by target population and WHO region (2007-2013) Figure 10 Evaluated grey literature strategies by target population and WHO region (1996-2013) Figure 11 Evaluated peer reviewed strategies by theme (2007-2013) Figure 12 Evaluated grey literature strategies by theme (1996-2013) Figure 13 Evaluated peer reviewed strategies by outcome (2007-2013) Figure 14 Evaluated grey literature strategies by outcome (1996-2013) Figure 15 Evaluated peer reviewed and grey literature strategies by the SAGE WG Model of Determinants of Vaccine Hesitancy Figure 16: Evaluated and suggested strategies for RHT hesitancy by WHO region Figure 17: Evaluated strategies by RHT and WHO region Figure 18: Evaluated strategies by target population and WHO region Figure 19: Evaluated strategies by theme Figure 20: Evaluated and suggested strategies for RHT (coded to the SAGE WG Model of Determinants of Vaccine Hesitancy) Figure 21: Effect of incentive-based, multi-component and other interventions on uptake of Hepatitis A and B vaccines; Evidence from the peer reviewed literature Figure 22: Effect of dialogue-based, incentive-based, multi-component, reminder / recall and other interventions on uptake of HPV vaccination; Evidence from the peer reviewed literature Figure 23: Effect of dialogue based, incentive-based, multi-component, reminder / recall and other interventions on uptake of influenza vaccination; Evidence from the peer reviewed literature Figure 24: Effect of dialogue based, incentive based, multi-component, reminder / recall and other interventions on uptake of individual childhood vaccination; Evidence from the peer reviewed literature 2 Figure 25: Effect of dialogue based, incentive based, multi-component, reminder / recall and other interventions on uptake of combined childhood vaccinations; Evidence from the peer reviewed literature Figure 26: Effect of a dialogue-based, incentive based multi-component, reminder / recall and other interventions on uptake of adult and adolescent vaccines; Evidence from the peer reviewed literature Figure 27: Effect of dialogue based and multi-component interventions on vaccine uptake; Evidence from the grey literature Figure 28: Effect of dialogue based, multi-component and other interventions on knowledge, awareness and attitudes to vaccination; Evidence from the peer reviewed literature Figure 29: Effect of multi-component and other intervention types on knowledge, awareness and attitudes to vaccination; Evidence
Load more

Recommended publications
  • The Implementation of Mass-Vaccination Against SARS-Cov-2: a Systematic Review of Existing Strategies and Guidelines
    Review The Implementation of Mass-Vaccination against SARS-CoV-2: A Systematic Review of Existing Strategies and Guidelines Tasnim Hasan 1,2, Justin Beardsley 1, Ben J. Marais 3 , Thu Anh Nguyen 2 and Greg J. Fox 1,2,* 1 Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; [email protected] (T.H.); [email protected] (J.B.) 2 The Woolcock Institute of Medical Research, Glebe, NSW 2037, Australia; [email protected] 3 Marie Bahir Institute, The University of Sydney, Westmead, NSW 2145, Australia; [email protected] * Correspondence: [email protected] Abstract: The global drive to vaccinate against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) began in December 2020 with countries in Europe, Middle East, and North America leading the roll out of a mass-vaccination program. This systematic review synthesised all available English-language guidelines and research regarding mass-vaccination for COVID-19 until 1 March 2021—the first three months of the global mass-vaccination effort. Data were extracted from national websites, PubMed, Embase, Medline and medRxiv, including peer and non-peer review research findings. A total of 15 national policy documents were included. Policies were summarised according to the World Health Organisation (WHO) framework for mass vaccination. All included policies prioritised front-line health care workers and the elderly. Limited information was available regarding staffing, cold chain, communication strategies and infrastructure requirements for effective vaccine Citation: Hasan, T.; Beardsley, J.; delivery. A total of 26 research studies were identified, reporting roll-out strategies, vaccine uptake Marais, B.J.; Nguyen, T.A.; Fox, G.J.
    [Show full text]
  • From the Factory to the Frontlines the Operation Warp Speed Strategy for Distributing a COVID-19 Vaccine
    From the Factory to the Frontlines The Operation Warp Speed Strategy for Distributing a COVID-19 Vaccine What This Strategy Aims to Do This report to Congress details a strategy to achieve the principal purpose and objective of Operation Warp Speed (OWS): ensuring that every American who wants to receive a COVID-19 vaccine can receive one, by delivering safe and effective vaccine doses to the American people beginning January 2021. The leadership of OWS has committed to being transparent with Congress, the media, and the American people. OWS has provided regular briefings on topics of interest to Congress and the media and will continue to provide updates and announcements as OWS reaches new milestones. Congress has been a vital partner in the all-of-America response to the COVID-19 pandemic. With support provided through emergency supplemental and flexible discretionary funding, OWS has now made strong progress toward a safe and effective COVID-19 vaccine, with multiple candidates in Phase 3 clinical trials. Simultaneously, OWS and partners are developing a plan for delivering a safe and effective product to Americans as quickly and reliably as possible. Experts from the Department of Health and Human Services (HHS) are leading vaccine development, while experts from the Department of Defense (DoD) are partnering with the Centers for Disease Control and Prevention (CDC) and other parts of HHS to coordinate supply, production, and distribution of vaccines. Successful implementation of the national COVID-19 vaccination program requires precise coordination across federal, state, local, tribal, and territorial governments and among many public and private partners.
    [Show full text]
  • 2020 Standards for Health Promoting Hospitals and Health Services
    2020 Standards for Health Promoting Hospitals and Health Services The International Network of Health Promoting Hospitals and Health Services The International HPH Secretariat is based out of the office of OptiMedis AG: Burchardstrasse 17 20095 Hamburg Germany Phone: +49 40 22621149-0 Fax: +49 40 22621149-14 Email: [email protected] © The International Network of Health Promoting Hospitals and Health Services 2020 The International Network of Health Promoting Hospitals and Health Services welcomes requests for permission to translate or reproduce this document in part or full. Please seek formal permission from the International HPH Secretariat. Recommended citation: International Network of Health Promoting Hospitals and Health Services. 2020 Standards for Health Promoting Hospitals and Health Services. Hamburg, Germany: International HPH Network; December, 2020. Acknowledgements This document is the result of the efforts of many individuals and groups dedicated to the implementation of health promotion in and by hospitals and health services. We would like to thank members of the International HPH Network for their support of and input to the development process and all former and current leaders and members of HPH Task Forces and Working Groups for the production of standards on which this comprehensive standards set is based. Special thanks are due to National and Regional HPH Network Coordinators, subject experts, Standing Observers, and our Governance Board who devoted their time and provided invaluable input during consultation processes. We would further like to acknowledge Dr. Rainer Christ, Ms. Birgit Metzler, Ms. Keriin Katsaros, Dr. Sally Fawkes, and Prof. Margareta Kristenson who advised on the process leading to this document and critically assessed its content.
    [Show full text]
  • Vaccines for Preteens
    | DISEASES and the VACCINES THAT PREVENT THEM | INFORMATION FOR PARENTS Vaccines for Preteens: What Parents Should Know Last updated JANUARY 2017 Why does my child need vaccines now? to get vaccinated. The best time to get the flu vaccine is as soon as it’s available in your community, ideally by October. Vaccines aren’t just for babies. Some of the vaccines that While it’s best to be vaccinated before flu begins causing babies get can wear off as kids get older. And as kids grow up illness in your community, flu vaccination can be beneficial as they may come in contact with different diseases than when long as flu viruses are circulating, even in January or later. they were babies. There are vaccines that can help protect your preteen or teen from these other illnesses. When should my child be vaccinated? What vaccines does my child need? A good time to get these vaccines is during a yearly health Tdap Vaccine checkup. Your preteen or teen can also get these vaccines at This vaccine helps protect against three serious diseases: a physical exam required for sports, school, or camp. It’s a tetanus, diphtheria, and pertussis (whooping cough). good idea to ask the doctor or nurse every year if there are any Preteens should get Tdap at age 11 or 12. If your teen didn’t vaccines that your child may need. get a Tdap shot as a preteen, ask their doctor or nurse about getting the shot now. What else should I know about these vaccines? These vaccines have all been studied very carefully and are Meningococcal Vaccine safe.
    [Show full text]
  • Vaccinator Training Plan Workstream 4: Vaccine Process and Workforce Subgroup 3: Workforce Planning and Training
    Vaccinator Training Plan Workstream 4: Vaccine Process and Workforce Subgroup 3: Workforce Planning and Training Health Service Executive Vaccinator Training Plan COVID-19 Vaccination Programme Subgroup 3: Workforce Planning and Prepared by Training [New Vaccinator Working Group] David Walsh, Workstream Lead Approved by Vaccination Process and Workforce Date 15th April2021 Version 02 1 Vaccinator Training Plan Workstream 4: Vaccine Process and Workforce Subgroup 3: Workforce Planning and Training Table of Contents Introduction .................................................................................................................................................... 3 Scope of the Training Programme .................................................................................................................. 3 Training Programme Delivery Approach ........................................................................................................ 6 Develop Training Programmes.................................................................................................................... 6 Deliver Vaccinator Training ......................................................................................................................... 7 Delivering the Training .................................................................................................................................... 9 Introduction ...............................................................................................................................................
    [Show full text]
  • Provided By: Techserve Alliance
    Provided by: TechServe Alliance Table of Contents Introduction .............................................................................................. 4 Return-to-Work at a Glance ....................................................................... 5 COVID-19 Return-to-Work Plans ..................................................................................... 5 Other Return-to-Work Considerations ........................................................................... 7 COVID-19 Vaccine Overview ....................................................................... 8 COVID-19 Vaccines and the Workplace ..................................................... 11 Government Guidance Related to COVID-19 Vaccines and Workplaces ...................11 OSHA Perspective ............................................................................... 11 EEOC Perspective ................................................................................ 11 Deciding Between a Mandatory or Voluntary Vaccination Policy ..............................13 General Employer Considerations ..................................................... 13 The Case for Mandatory Workplace Vaccination............................. 14 The Case for Voluntary Workplace Vaccination ............................... 14 Developing a Workplace Vaccination Plan ...................................................................16 Step 1: Gauge the Situation .............................................................. 16 Step 2: Make the Choice ...................................................................
    [Show full text]
  • Would Parents Get Their Children Vaccinated Against SARS-Cov-2? Rate and Predictors of Vaccine Hesitancy According to a Survey Over 5000 Families from Bologna, Italy
    Article Would Parents Get Their Children Vaccinated Against SARS-CoV-2? Rate and Predictors of Vaccine Hesitancy According to a Survey over 5000 Families from Bologna, Italy Marco Montalti 1,* , Flavia Rallo 1, Federica Guaraldi 2, Lapo Bartoli 3, Giulia Po 4 , Michela Stillo 5, Paola Perrone 5, Lorena Squillace 5, Laura Dallolio 1 , Paolo Pandolfi 5, Davide Resi 5, Maria Pia Fantini 1 , Chiara Reno 1 and Davide Gori 1 1 Unit of Hygiene, Department of Biomedical and Neuromotor Sciences, Public Health and Medical Statistics, University of Bologna, 40126 Bologna, Italy; fl[email protected] (F.R.); [email protected] (L.D.); [email protected] (M.P.F.); [email protected] (C.R.); [email protected] (D.G.) 2 IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy; [email protected] 3 Unit of Primary Health Care, Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy; [email protected] 4 School of Hygiene and Preventive Medicine, University of Ferrara, 44121 Ferrara, Italy; [email protected] 5 Department of Public Health, Bologna Local Health Authority, 40124 Bologna, Italy; [email protected] (M.S.); [email protected] (P.P.); [email protected] (L.S.); paolo.pandolfi@ausl.bologna.it (P.P.); [email protected] (D.R.) * Correspondence: [email protected]; Tel.: +39-051-209-4802 Citation: Montalti, M.; Rallo, F.; Guaraldi, F.; Bartoli, L.; Po, G.; Stillo, Abstract: In the near future, COVID-19 vaccine efficacy trials in larger cohorts may offer the possibility M.; Perrone, P.; Squillace, L.; Dallolio, to implement child and adolescent vaccination.
    [Show full text]
  • Promoting Hygiene
    74 CHAPTER 9 Promoting hygiene The goal of hygiene promotion is to help people to understand and develop good hygiene practices, so as to prevent disease and promote positive atti- tudes towards cleanliness. Several community development activities can be used to achieve this goal, including education and learning programmes, encouraging community management of environmental health facilities, and social mobilization and organization. Hygiene promotion is not simply a matter of providing information. It is more a dialogue with communities about hygiene and related health problems, to encourage improved hygiene practices. Some key steps for establishing a hygiene promotion project, possibly with support from an outside agency, are listed in the text box below. Establishing a hygiene promotion project • Evaluate whether current hygiene practices are good/safe. • Plan which good hygiene practices to promote. • Implement a health promotion programme that meets community needs and is understandable by everyone. • Monitor and evaluate the programme to see whether it is meeting targets. 9.1 Assessing hygiene practices To assess whether good hygiene is practised by your community, some of the methods discussed in section 2.2 can be used. It is particularly important to identify behaviours that spread pathogens. The following are the riskiest behaviours: • The unsafe disposal of faeces. • Not washing hands with soap after defecating. • The unsafe collection and storage of water. CHAPTER 9. PROMOTING HYGIENE 75 Key questions for assessing hygiene
    [Show full text]
  • Public Health Promotion and Protection, Disease Prevention,And Emergency Preparedness
    Chapter 3 Strategic Goal 2: Public Health Promotion and Protection, Disease Prevention,and Emergency Preparedness Prevent and control disease, injury, illness, and disability across the lifespan, and protect the public from infectious, occupational, environmental, and terrorist threats. CHAPTER 3: PUBLIC HEALTH PROMOTION AND PROTECTION, DISEASE PREVENTION,AND EMERGENCY PREPAREDNESS Throughout the 20th century, advances in public health and medicine resulted in reduced morbidity and mortality STRATEGIC GOAL 2: from infectious diseases, including influenza, polio, and PUBLIC HEALTH PROMOTION AND PROTECTION, foodborne and waterborne illnesses. Chronic diseases, DISEASE PREVENTION, AND EMERGENCY such as heart disease, stroke, cancer, and diabetes, PREPAREDNESS replaced infectious diseases as the major cause of illness Strategic Objective 2.1: and death in the United States in the latter part of the 20th Prevent the spread of infectious diseases. century. In the new millennium, the Nation continues to face the challenge of chronic disease because of unhealthy Strategic Objective 2.2: and risky behaviors, environmental exposures, and an Protect the public against injuries and aging population. environmental threats. Strategic Objective 2.3: Promote and encourage preventive health care, including mental health, lifelong healthy behaviors, and recovery. Strategic Objective 2.4: Prepare for and respond to natural and manmade disasters. HHS STRATEGIC PLAN FY 2007-2012 59 CHAPTER 3: PUBLIC HEALTH PROMOTION AND PROTECTION, DISEASE PREVENTION,AND EMERGENCY PREPAREDNESS Today, chronic diseases continue to be significant health The 21st century is also marked by the threat of public problems that face Americans. As HHS works to address health emergencies. These threats have become a these health issues, infectious diseases have reemerged significant focus for public health at the Federal, State, as a priority for public health in the United States.
    [Show full text]
  • Hygiene Promotion – Hubley, J
    WATER AND HEALTH – Vol. I - Hygiene Promotion – Hubley, J. HYGIENE PROMOTION Hubley J. Leeds Metropolitan University, Leeds, United Kingdom Keywords: hygiene promotion, hygiene behaviours; health education; community participation, mass media; schools. Contents 1. Introduction 1.1 Terminology 1.2. The importance of hygiene promotion 2. Overviews of hygiene promotion 2.1 Component activities of hygiene promotion 3. Situation analysis 3.1 General information required in situation analysis 3.2. Identification of target hygiene practices 3.3. Community participation in assessing needs 4. Planning and implementation of hygiene promotion 4.1 Service improvement component 4.2. Advocacy component 4.4.3 Health education component 4.3.1 Who should it be directed at? 4.3.2 Who should carry out the health education? 4.3.3 What should the health education consist of? 4.3.4 How should the education be carried out? 5. Monitoring and evaluation of hygiene promotion 6. Conclusions Glossary Bibliography Biographical Sketch Summary Hygiene promotion involves activities directed towards the improvement in health through UNESCOthe promotion of uptake, maintenan – ceEOLSS and use of water and sanitation systems and accompanying support behaviours such as appropriate storage and use of water in the home, washingSAMPLE of hands and face, safe disposal CHAPTERS of faeces and hygienic preparation of food. Effective hygiene promotion usually involves a mix of three activities: health education directed at individuals, families and communities to adopt hygiene behaviours, service improvements such as the development of outreach and support services and latrine components, and advocacy directed at encouraging appropriate policies. The first step in carrying out hygiene promotion is an assessment of the target community to determine the relative importance of different disease transmission routes, current hygiene practices, beliefs and other factors which determine those ©Encyclopedia of Life Support Systems (EOLSS) WATER AND HEALTH – Vol.
    [Show full text]
  • Summary of Supportive Science Regarding Thimerosal Removal
    Summary of Supportive Science Regarding Thimerosal Removal Updated December 2012 www.safeminds.org Science Summary on Mercury in Vaccines (Thimerosal Only) SafeMinds Update – December 2012 Contents ENVIRONMENTAL IMPACT ................................................................................................................................. 4 A PILOT SCALE EVALUATION OF REMOVAL OF MERCURY FROM PHARMACEUTICAL WASTEWATER USING GRANULAR ACTIVATED CARBON (CYR 2002) ................................................................................................................................................................. 4 BIODEGRADATION OF THIOMERSAL CONTAINING EFFLUENTS BY A MERCURY RESISTANT PSEUDOMONAS PUTIDA STRAIN (FORTUNATO 2005) ......................................................................................................................................................................... 4 USE OF ADSORPTION PROCESS TO REMOVE ORGANIC MERCURY THIMEROSAL FROM INDUSTRIAL PROCESS WASTEWATER (VELICU 2007)5 HUMAN & INFANT RESEARCH ............................................................................................................................ 5 IATROGENIC EXPOSURE TO MERCURY AFTER HEPATITIS B VACCINATION IN PRETERM INFANTS (STAJICH 2000) .................................. 5 MERCURY CONCENTRATIONS AND METABOLISM IN INFANTS RECEIVING VACCINES CONTAINING THIMEROSAL: A DESCRIPTIVE STUDY (PICHICHERO 2002) ......................................................................................................................................................
    [Show full text]
  • Supplemental Information and Guidance for Vaccination Providers Regarding Use of 9-Valent HPV Vaccine
    Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV A 9-valent human papillomavirus (HPV) vaccine (9vHPV, Gardasil 9, Merck & Co.) was licensed for use in females and males in December 2014.1,2,3,4 The 9vHPV was the third HPV vaccine licensed in the United States by the Food and Drug Administration (FDA); the other vaccines are bivalent HPV vaccine (2vHPV, Cervarix, GlaxoSmithKline), licensed for use in females, and quadrivalent HPV vaccine (4vHPV, Gardasil, Merck & Co.), licensed for use in females and males.5 In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended 9vHPV as one of three HPV vaccines that can be used for routine vaccination of females and one of two HPV vaccines for routine vaccination of males.6 After the end of 2016, only 9vHPV will be distributed in the United States. In October 2016, ACIP updated HPV vaccination recommendations regarding dosing schedules.7 CDC now recommends two doses of HPV vaccine (0, 6–12 month schedule) for persons starting the vaccination series before the 15th birthday. Three doses of HPV vaccine (0, 1–2, 6 month schedule) continue to be recommended for persons starting the vaccination series on or after the 15th birthday and for persons with certain immunocompromising conditions. Guidance is needed for persons who started the series with 2vHPV or 4vHPV and may be completing the series with 9vHPV. The information below summarizes some of the recommendations included in ACIP Policy Notes and provides additional guidance.5-7 Information about the vaccines What are some of the similarities and differences between the three HPV vaccines? y Each of the three HPV vaccines is a noninfectious, virus-like particle (VLP) vaccine.
    [Show full text]